Cormedix Inc (CRMD)
4.24
+0.08
(+1.92%)
USD |
NASDAQ |
Mar 28, 16:00
4.235
0.00 (0.00%)
After-Hours: 20:00
Cormedix Research and Development Expense (Quarterly): 2.289M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 2.289M |
September 30, 2023 | 2.664M |
June 30, 2023 | 4.795M |
March 31, 2023 | 3.408M |
December 31, 2022 | 2.843M |
September 30, 2022 | 2.339M |
June 30, 2022 | 3.210M |
March 31, 2022 | 2.288M |
December 31, 2021 | 3.235M |
September 30, 2021 | 4.741M |
June 30, 2021 | 2.520M |
March 31, 2021 | 2.636M |
December 31, 2020 | 2.294M |
September 30, 2020 | 2.925M |
June 30, 2020 | 5.685M |
March 31, 2020 | 2.472M |
December 31, 2019 | 2.677M |
September 30, 2019 | 2.521M |
June 30, 2019 | 2.980M |
March 31, 2019 | 2.875M |
December 31, 2018 | -4.347M |
September 30, 2018 | 8.289M |
June 30, 2018 | 6.600M |
March 31, 2018 | 8.280M |
December 31, 2017 | 8.458M |
Date | Value |
---|---|
September 30, 2017 | 6.014M |
June 30, 2017 | 5.090M |
March 31, 2017 | 4.924M |
December 31, 2016 | 4.032M |
September 30, 2016 | 6.840M |
June 30, 2016 | 2.773M |
March 31, 2016 | 2.090M |
December 31, 2015 | 1.485M |
September 30, 2015 | 1.764M |
June 30, 2015 | 1.798M |
March 31, 2015 | 1.234M |
December 31, 2014 | 0.5011M |
September 30, 2014 | 0.2927M |
June 30, 2014 | 0.1719M |
March 31, 2014 | 0.353M |
December 31, 2013 | -0.1591M |
September 30, 2013 | 0.7508M |
June 30, 2013 | 0.3802M |
March 31, 2013 | 0.255M |
December 31, 2012 | 0.2976M |
September 30, 2012 | 0.2445M |
June 30, 2012 | 0.2369M |
March 31, 2012 | 0.3636M |
December 31, 2011 | -0.4245M |
September 30, 2011 | 1.725M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.288M
Minimum
Mar 2022
5.685M
Maximum
Jun 2020
3.070M
Average
2.760M
Median
Research and Development Expense (Quarterly) Benchmarks
Johnson & Johnson | 4.48B |
Bristol-Myers Squibb Co | 2.478B |
BioXcel Therapeutics Inc | 9.934M |
ACADIA Pharmaceuticals Inc | 66.74M |
Amicus Therapeutics Inc | 35.03M |